FLT3 and acute myeloid leukemia: The rationale for this approach is target-specific: FLT3-ITD is one of the most frequent mutations in AML, occurring in approximately 25–30% of adults and 10–15% of pediatric patients, and is associated with high relapse risk and poorer prognosis (30).